Undisclosed Metabolic Disruptor

About Analona Therapeutics

Analona Therapeutics is a private, preclinical-stage biotech based in Copenhagen, Denmark, founded in 2024. The company is developing first-in-class antibody therapeutics aimed at disrupting tumor metabolism, with an initial focus on a novel target involved in metabolite transport. Led by a seasoned team with deep expertise in oncology drug development and cancer biology, Analona is positioned to address high-need solid tumors, though it remains at an early, pre-revenue stage with significant execution and scientific risk.

Therapeutic Areas